Pfizer: positive results in bacterial infections
(CercleFinance.com) - Pfizer last night announced positive results from a phase 3 program evaluating the efficacy, safety and tolerability of the new investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in the treatment of serious bacterial infections caused by Gram-negative bacteria, including multi-drug resistant pathogens for which there are few or no treatment options.
The data confirm that ATM-AVI is effective and well tolerated, with no new safety findings and a similar safety profile to aztreonam alone.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The data confirm that ATM-AVI is effective and well tolerated, with no new safety findings and a similar safety profile to aztreonam alone.
Copyright (c) 2023 CercleFinance.com. All rights reserved.